TheraBiogen, Inc. (OTC.BB: TRAB) is pleased to announce it is in agreement with Walgreens for distribution nationally in all their approximately 7500 locations for the 2011-2012 cold and flu season.

TheraBiogen has been selling TheraMax® Cold & Flu Relief and TheraMax® Allergy Relief since the beginning of the 2010 Fall season. Consumers nationwide have embraced the new products in their initial launch. Kelly Hickel, CEO of TheraBiogen, Inc., said, “We are very excited that Walgreens, the number one drug retailer in the world, will make TheraMax® Cold & Flu Relief available to consumers in all their locations nationally. As we expand distribution, we expect to see the same continued support from consumers that we have seen since our launch last fall.”

About TheraBiogen, Inc.

TheraBiogen, Inc. is the manufacturer and distributor of homeopathic nasal sprays for aiding in the relief of allergies and cold and flu symptoms. The products are made from natural, homeopathic ingredients and contain no zinc, which has been identified as potentially causing nasal problems in other similar products on the market. For further information please visit www.theramaxrelief.com or our Facebook page at facebook.com/theramaxnasalspray.

Safe Harbor Statement

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21 E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risk that could cause actual performance and results of operations to differ materially from those anticipated. These risks are set forth in the Company’s most recently filed form 10-K and Form 10-Q reports. TheraBiogen, Inc. assumes no obligation to update the statements contained in this release except as required by applicable securities disclosure rules.

Sinobiopharma, Inc. (SNBP) is pleased to announce that its production facility for solid dosage Perindopril has passed the required Chinese State Food and Drug Administration (SFDA) inspection and is now approved for production and marketing.

Sinobiopharma had received SFDA approval for its formulation of Perindopril, the first version of the drug to be developed in China, in April 2009.  SFDA regulations require that drug makers conduct large-scale production of at least three batches of a newly approved drug in a Good Manufacturing Practice (GMP) certified production facility. SFDA officials inspect the production process, the application of GMP standards, and conducted a full test of randomly picked samples of the drug. Sinobiopharma successfully met all the requirements and now has received approval to distribute the drug throughout China.

The Company believes its formulation of Perindopril is the latest generation worldwide of the product, which is part of a class of medications known as angiotensin-converting enzyme (ACE) inhibitors. These medications are used alone or in combination with other medications to treat high blood pressure.  Perindopril allows blood to flow more smoothly by preventing the production of certain natural chemicals that constrict blood vessels.  Every year, US$3.7 billion is spent on the treatment of hypertension in China.  Sinibiopharma’s Perindopril will be marketed under the trade name YiTai in China.

“We believe that YiTai is a first-to-market drug in China and therefore enjoys the benefit of having a government sanctioned price premium as well as certain exclusive marketing rights to hospitals,” said Dr. Lequn Lee Huang, CEO of the Company. “The market for anti-hypertensives in China is huge, but highly fragmented. Sinobiopharma’s YiTai is well positioned to capture substantial market share quickly.”

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative specialty biopharmaceutical company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, one of the world’s fastest growing pharmaceutical markets. Known as Dong Ying (Jiangsu) Pharmaceutical Co., Ltd. in China, the Company’s current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include “forward-looking statements” regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward looking statement, except as required under applicable law.